Cardiometabolic
ADA 2026 findings show diabetes drugs are no longer just chasing glucose
New phase 3 findings presented at ADA 2026 suggest the next wave of cardiometabolic therapies is moving beyond blood sugar control and weight loss, towards broader effects on liver fat, cardiovascular risk markers, sleep apnoea and obesity-related complications.
India’s Obesity Campaign Dispute Tests the Line Between Awareness and Promotion
England’s Tirzepatide Rollout Shows Approval Is Not Access
Medicare’s GLP-1 Bridge Turns Obesity Coverage Into a Public-Payer Experiment
WHO Makes Obesity Treatment a Global Access Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.